DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix
Journal for ImmunoTherapy of Cancer · 2026-02 · 14 (2) · e012805
DOI: 10.1136/jitc-2025-012805 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 11.02.2026. Verfasst von Young Kwang Chae und 33 weiteren Autor:innen. Beteiligte Einrichtung: Northwestern University, Chicago, Illinois, USA chaelabmeeting@gmail.com patel@ucsd.edu rkurzrock@mcw.edu. Hauptthemen laut MEDLINE: Adenocarcinoma, Clear Cell, Antineoplastic Combined Chemotherapy Protocols, Endometrial Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health/National Cancer Institute, Bristol Myers Squibb Foundation.
Abstract (Originalsprache)
Background
Dual anti-CTLA-4/PD-1 inhibitors show efficacy in numerous malignancies. We are the first to report on the efficacy of ipilimumab-nivolumab immunotherapy in a dedicated cohort of patients with gynecologic clear cell carcinomas (CCCs), which are rare, aggressive cancers.
Methods
DART is a multicenter, multicohort phase II trial of ipilimumab (1 mg/kg intravenously every 6 weeks) plus nivolumab (240 mg intravenously every 2 weeks), with primary objective as Response Evaluation Criteria in Solid Tumors (RECIST)-based overall response rate (ORR). Secondary objectives were ORR by immune RECIST (iRECIST), progression-free survival (PFS), overall survival (OS), clinical benefit rate (CBR; overall response plus stable disease (SD) ≥6 months), and toxicity.
Results
Overall, in this cohort of 32 patients with gynecologic CCC (N=19 ovarian, N=8 endometrial, N=5 cervical; 1–8 prior therapies; 3 had prior PD-1 inhibitor exposure), an ORR of 9.38% was seen. This included two complete responses (CRs) (both ovarian origin) that are ongoing at >3 years and one partial response (PR). Overall ORR increased to 12.5% when including one PR by iRECIST criteria for a patient with cervical CCC lasting 26 months, with an OS of 32.0 months. The CBR was 21.88% overall for all 32 (7/32) evaluable patients with gynecologic CCC. This included two CR, one PR, and two patients with SD >6 months with ovarian CCC and one PR by iRECIST and one SD >6 months in two patients with cervical CCC. PFS for the seven patients with CBR was 63.6+, 47.8+, 40.5+, 50.8+, 7.4, 26, and 58.1+ months. Median OS was 21.7 months for all 32 evaluable patients. Seven of 32 patients (21.9%) discontinued therapy because of toxicity; there were no treatment-related deaths.
Conclusions
Ipilimumab plus nivolumab demonstrated durable antitumor activity in certain patients with CCC of gynecological origin, particularly in those with CCC of ovarian origin. Safety is consistent with the known profile of ipilimumab and nivolumab. Correlative studies to better identify which patients will respond to combined ipilimumab and nivolumab are ongoing. Trial registration number NCT02834013 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Northwestern University, Chicago, Illinois, USA chaelabmeeting@gmail.com patel@ucsd.edu rkurzrock@mcw.edu.
- SWOG Statistics and Data Management Center, Seattle, Washington, USA.
- University of California at San Diego Moores Cancer Center, Sacramento, La Jolla, USA chaelabmeeting@gmail.com patel@ucsd.edu rkurzrock@mcw.edu.
- Ohio State University, Columbus, Ohio, USA.
- City of Hope Comprehensive Cancer Center, Duarte, California, USA.
- MD Anderson Cancer Center, Houston, Texas, USA.
Förderung
- NCI NIH HHS
- National Institutes of Health/National Cancer Institute
- Bristol Myers Squibb Foundation
Zitieren
APA
Chae, Y. K., Othus, M., Patel, S. P., Backes, F. J., O'Malley, D. M., Cristea, M., Naing, A., Kurnit, K., Eskander, R. N., T Goodrich, S., Robinson, W. R., Scalici, J., Chan, J., Ali-Ahmad, H., Hays, J., McCormick, C., Kim, E. J., Sueblinvong, T., Ahmed, A., …, & Kurzrock, R. (2026). DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix. Journal for ImmunoTherapy of Cancer, 14(2), e012805. https://doi.org/10.1136/jitc-2025-012805
Vancouver
Chae YK, Othus M, Patel SP, Backes FJ, O'Malley DM, Cristea M, et al. DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix. Journal for ImmunoTherapy of Cancer. 2026;14(2):e012805. doi:10.1136/jitc-2025-012805
BibTeX
@article{Chae2026,
author = {Chae, Young Kwang and Othus, Megan and Patel, Sandip P and Backes, Floortje J and O'Malley, David M and Cristea, Mihaela and Naing, Aung and Kurnit, Katherine and Eskander, Ramez N and T Goodrich, Scott and Robinson, William R and Scalici, Jennifer and Chan, John and Ali-Ahmad, Hussein and Hays, John and McCormick, Colleen and Kim, Edward J and Sueblinvong, Thanasak and Ahmed, Amina and Siedel, Jean and Thomes Pepin, Jessica and Bottsford-Miller, Justin Neal and Fagbemi, Seth Olusegun and Jaslowski, Anthony John and Kim, Hye Sung and Chung, Liam Il-Young and Moloney-Lineen, Carolyn and McLeod, Christine M and Chen, Helen X and Sharon, Elad and Streicher, Howard and Ryan, Christopher W and Blanke, Charles D and Kurzrock, Razelle},
title = {DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {2},
pages = {e012805},
doi = {10.1136/jitc-2025-012805}
}
EUVIMED